Gobburu JV - Search Results

1

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.

Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R. Goodman VL, et al. Among authors: gobburu jv. Clin Cancer Res. 2007 Mar 1;13(5):1367-73. doi: 10.1158/1078-0432.CCR-06-2328. Clin Cancer Res. 2007. PMID: 17332278 Review.

2

Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation.

Procaccini DE, Roem J, Ng DK, Rappold TE, Jung D, Gobburu JVS, Bembea MM. Procaccini DE, et al. Br J Clin Pharmacol. 2023 Aug;89(8):2396-2406. doi: 10.1111/bcp.15703. Epub 2023 Mar 20. Br J Clin Pharmacol. 2023. PMID: 36850024 Free article.

3

Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework.

Langevin B, Gobburu JVS, Gopalakrishnan M. Langevin B, et al. J Clin Pharmacol. 2023 Nov;63 Suppl 2:S48-S64. doi: 10.1002/jcph.2304. J Clin Pharmacol. 2023. PMID: 37942905

4

The trajectory of pharmacometrics to support drug licensing and labelling.

Dunn A, Gobburu JVS. Dunn A, et al. Br J Clin Pharmacol. 2023 Apr 2. doi: 10.1111/bcp.15728. Online ahead of print. Br J Clin Pharmacol. 2023. PMID: 37005339 Free article. Review.

5

Evaluating the indotecan-neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal E_max regressions.

Beumer JH, Kennard BC, Holleran JL, Moore N, Zlott J, Miller BM, Kummar S, Chen A, Doroshow J, Park W, Gobburu J, Dunn A. Beumer JH, et al. Cancer Chemother Pharmacol. 2023 Mar;91(3):219-230. doi: 10.1007/s00280-023-04509-8. Epub 2023 Feb 23. Cancer Chemother Pharmacol. 2023. PMID: 36813886 Free PMC article.

6

A convolution-based in vitro-in vivo correlation model for methylphenidate hydrochloride delayed-release and extended-release capsule.

Gupta PK, Incledon B, Gobburu JVS, Gomeni R. Gupta PK, et al. CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):132-142. doi: 10.1002/psp4.13067. Epub 2023 Oct 31. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 37864318 Free PMC article.

7

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R. Cohen MH, et al. Clin Cancer Res. 2002 May;8(5):935-42. Clin Cancer Res. 2002. PMID: 12006504

8

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R. Dagher R, et al. Clin Cancer Res. 2002 Oct;8(10):3034-8. Clin Cancer Res. 2002. PMID: 12374669 Clinical Trial.

9

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R. Ibrahim A, et al. Among authors: gobburu jv. Clin Cancer Res. 2003 Jul;9(7):2394-9. Clin Cancer Res. 2003. PMID: 12855610 Clinical Trial.

10

Considerations in analyzing single-trough concentrations using mixed-effects modeling.

Booth BP, Gobburu JV. Booth BP, et al. Among authors: gobburu jv. J Clin Pharmacol. 2003 Dec;43(12):1307-15. doi: 10.1177/0091270003258670. J Clin Pharmacol. 2003. PMID: 14615466

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

145 results

Search Page

Filters